Premium
The impact of bone loss in women with endometriosis
Author(s) -
Stevenson J.C
Publication year - 1995
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/0020-7292(95)02509-b
Subject(s) - medicine , danazol , endometriosis , osteoporosis , bone density , agonist , gonadotropin releasing hormone agonist , peak bone mass , endocrinology , bone mineral , bone remodeling , receptor , buserelin
Low peak adult bone mass in a premenopausal woman puts her at increased risk for osteoporosis postmenopausally. Episodes of hypo‐estrogenism premenopausally are associated with loss of bone density. This is seen with gonadotropin‐releasing hormone agonist therapy for endometriosis, and thus prolonged or repeated courses of such treatment may increase the future risk of osteoporosis. Danazol and related compounds do not result in any bone loss but may have certain metabolic disadvantages.